Bicycle Therapeutics (BCYC) Operating Income (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Operating Income data on file, last reported at -$54.6 million in Q2 2026.

• Quarterly Operating Income rose 37.0% year-over-year to -$54.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$210.3 million (up 27.06% YoY) and the FY2025 annual result came in at -$247.1 million, down 17.72% from the prior year.
• Operating Income advanced to -$54.6 million in Q2 2026, from -$65.5 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$24.7 million in Q4 2025 to a low of -$86.6 million in Q2 2025.
• A 5-year average of -$49.1 million and a median of -$48.7 million in 2023 frame the typical range for Operating Income.
• The widest YoY moves for Operating Income: up 63.48% in 2025, down 121.35% in 2025.
• Tracing BCYC's Operating Income over 5 years: stood at -$32.2 million in 2022, then tumbled by 68.37% to -$54.2 million in 2023, then retreated by 24.76% to -$67.7 million in 2024, then surged by 63.48% to -$24.7 million in 2025, then tumbled by 120.82% to -$54.6 million in 2026.
• The last three Operating Income figures came in at -$54.6 million (Q2 2026), -$65.5 million (Q1 2026), and -$24.7 million (Q4 2025), per Business Quant data.